Neurotoxicity associated with CD19-targeted CAR-T cell therapies
Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
[PDF][PDF] Neurotoxicity Associated with CD19‑Targeted CAR‑T Cell Therapies
J Gust, A Taraseviciute, CJ Turtle - 2018 - researchgate.net
Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
J Gust, A Taraseviciute, CJ Turtle - CNS drugs, 2018 - pubmed.ncbi.nlm.nih.gov
Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
[引用][C] Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
J Gust, A Taraseviciute, CJ Turtle - CNS Drugs, 2018 - cir.nii.ac.jp
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.
J Gust, A Taraseviciute, CJ Turtle - CNS Drugs, 2018 - europepmc.org
Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
[HTML][HTML] Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
J Gust, A Taraseviciute, CJ Turtle - CNS drugs, 2018 - ncbi.nlm.nih.gov
Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
J Gust, A Taraseviciute, CJ Turtle - CNS Drugs, 2018 - search.proquest.com
Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …
therapies. Acute neurologic signs and/or symptoms occur in a significant proportion of …